FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

October 4, 2016

A new publication using BÜHLMANN Quantum Blue® fCAL is looking at the impact of using fecal Calprotectin in IBD management .

Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211.PMID:27688663.

“The FC test effected a change in management 51.3% of the time and receipt of the result was associated with a reduction in the number of colonoscopies performed.”

General Highlights from this Publication:

  1. Evaluation of the perspectives of gastroenterologists on use of fecal caloprotectin (FC) and the impact on management of subjects with inflammatory bowel disease (IBD)
  2. Outcomes stratified to FC test results
  3. Significance of FC testing
  4. Use of BÜHLMANN’s  Quantum Blue® fCAL for measuring FC levels in all stool samples
  5. Potential of FC to generate cost savings